{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:34:21Z","timestamp":1757619261062,"version":"3.44.0"},"reference-count":69,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Frontline Gastroenterol"],"accepted":{"date-parts":[[2016,10,17]]},"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:p>Primary biliary cholangitis (PBC) is an immunological condition that causes a significant health disturbance and dramatically reduces the quality of life for those affected with the disease. It is a potentially fatal disease that can lead to multiple hepatic and extrahepatic complications. Having adequate therapeutic interventions that can improve the course of the disease is imperative in reducing the associated morbidity and mortality. Ursodeoxycholic acid (UDCA) is the gold standard therapy. However, it has been associated with suboptimal response rates in a significant proportion of patients. Despite UDCA, approximately 35%\u201340% of individuals with PBC still experience a progression of the disease, leading to liver failure and requiring liver transplantation. Recent studies of new pharmacological approaches have shown beneficial outcomes. Some of these agents can now be applied to a clinical scenario. In this review article, we will outline the new and emerging treatments for PBC.<\/jats:p>","DOI":"10.1136\/flgastro-2016-100741","type":"journal-article","created":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T22:20:07Z","timestamp":1478211607000},"page":"29-36","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Primary biliary cholangitis: new treatments for an old disease"],"prefix":"10.1136","volume":"8","author":[{"given":"Hirsh D","family":"Trivedi","sequence":"first","affiliation":[{"name":"Liver Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blanca","family":"Lizaola","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, St. Elizabeth's Medical Center, Brighton, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elliot B","family":"Tapper","sequence":"additional","affiliation":[{"name":"Department of Hepatology, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Bonder","sequence":"additional","affiliation":[{"name":"Liver Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2016,11,3]]},"reference":[{"key":"2025090709015497000_8.1.29.1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22906"},{"issue":"2","key":"2025090709015497000_8.1.29.2","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000440757","article-title":"Fatigue in primary biliary cirrhosis: prevalence, pathogenesis and management","volume":"33","author":"Jopson","year":"2015","journal-title":"Dig Dis"},{"key":"2025090709015497000_8.1.29.3","first-page":"204","article-title":"Management of symptom complexes in primary biliary cholangitis","volume":"32","author":"Kuo","year":"2016","journal-title":"Curr Opin Gastroenterol"},{"key":"2025090709015497000_8.1.29.4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.gtc.2016.02.009","article-title":"Metabolic bone disease in primary biliary cirrhosis","volume":"45","author":"Glass","year":"2016","journal-title":"Gastroenterol Clin North Am"},{"key":"2025090709015497000_8.1.29.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.04.009"},{"key":"2025090709015497000_8.1.29.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80136-6"},{"key":"2025090709015497000_8.1.29.7","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S0140-6736(87)91610-2","article-title":"Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?","volume":"1","author":"Poupon","year":"1987","journal-title":"Lancet"},{"key":"2025090709015497000_8.1.29.8","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/0016-5085(89)91698-3","article-title":"Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial","volume":"97","author":"Leuschner","year":"1989","journal-title":"Gastroenterology"},{"key":"2025090709015497000_8.1.29.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199105303242204"},{"key":"2025090709015497000_8.1.29.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(97)70183-5"},{"key":"2025090709015497000_8.1.29.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199405123301903"},{"key":"2025090709015497000_8.1.29.12","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510290603"},{"key":"2025090709015497000_8.1.29.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)80216-0"},{"key":"2025090709015497000_8.1.29.14","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.01.003"},{"key":"2025090709015497000_8.1.29.15","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.12.029"},{"key":"2025090709015497000_8.1.29.16","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22428"},{"key":"2025090709015497000_8.1.29.17","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0528.2002.017402.x"},{"key":"2025090709015497000_8.1.29.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.02.031"},{"key":"2025090709015497000_8.1.29.19","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/hep.26322","article-title":"Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study","volume":"58","author":"Zhang","year":"2013","journal-title":"Hepatology"},{"key":"2025090709015497000_8.1.29.20","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.08.029"},{"key":"2025090709015497000_8.1.29.21","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1007\/s10620-010-1291-5","article-title":"Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid","volume":"55","author":"Kaplan","year":"2010","journal-title":"Dig Dis Sci"},{"key":"2025090709015497000_8.1.29.22","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"2025090709015497000_8.1.29.23","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/liv.12290","article-title":"Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid","volume":"34","author":"Lens","year":"2014","journal-title":"Liver Int"},{"key":"2025090709015497000_8.1.29.24","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/MOG.0000000000000056","article-title":"Fibrate treatment for primary biliary cirrhosis","volume":"30","author":"Cuperus","year":"2014","journal-title":"Curr Opin Gastroenterol"},{"key":"2025090709015497000_8.1.29.25","doi-asserted-by":"crossref","first-page":"490731","DOI":"10.1155\/2013\/490731","article-title":"Combination therapy of ursodeoxycholic acid and corticosteroids for primary biliary cirrhosis with features of autoimmune hepatitis: a meta-analysis","volume":"2013","author":"Zhang","year":"2013","journal-title":"Gastroenterol Res Pract"},{"key":"2025090709015497000_8.1.29.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70351-3"},{"key":"2025090709015497000_8.1.29.27","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20646"},{"key":"2025090709015497000_8.1.29.28","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0168-8278(11)60030-5","article-title":"An international study evaluating the farnesoid X receptor agonist obeticholic acid as monotherapy in PBC","volume":"54","author":"Kowdley","year":"2011","journal-title":"J Hepatol"},{"key":"2025090709015497000_8.1.29.29","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0168-8278(10)60004-9","article-title":"Farnesoid-x receptor agonists: a new class of drugs for the treatment of PBC? An international study evaluating the addition of INT-747 to ursodeoxycholic acid","volume":"52","author":"Mason","year":"2010","journal-title":"J Hepatol"},{"key":"2025090709015497000_8.1.29.30","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.12.005"},{"key":"2025090709015497000_8.1.29.31","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24748"},{"key":"2025090709015497000_8.1.29.32","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.068783"},{"key":"2025090709015497000_8.1.29.33","doi-asserted-by":"publisher","DOI":"10.1021\/jm901390p"},{"key":"2025090709015497000_8.1.29.34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0108270"},{"key":"2025090709015497000_8.1.29.35","doi-asserted-by":"publisher","DOI":"10.1124\/mol.110.064501"},{"key":"2025090709015497000_8.1.29.36","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24537"},{"key":"2025090709015497000_8.1.29.37","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jhep.2015.12.007","article-title":"ASBT inhibitors in cholangiopathies\u2014good for mice, good for men?","volume":"64","author":"Poupon","year":"2016","journal-title":"J Hepatol"},{"key":"2025090709015497000_8.1.29.38","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/hep.26067","article-title":"Therapeutic effect of cytotoxic T lymphocyte antigen 4\/immunoglobulin on a murine model of primary biliary cirrhosis","volume":"57","author":"Dhirapong","year":"2013","journal-title":"Hepatology"},{"key":"2025090709015497000_8.1.29.39","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/cei.12193","article-title":"Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis","volume":"174","author":"Tanaka","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"2025090709015497000_8.1.29.40","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jhep.2011.05.040","article-title":"Towards common denominators in primary biliary cirrhosis: the role of IL-12","volume":"56","author":"Lleo","year":"2012","journal-title":"J Hepatol"},{"key":"2025090709015497000_8.1.29.41","doi-asserted-by":"publisher","DOI":"10.1038\/nature01355"},{"key":"2025090709015497000_8.1.29.42","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M207577200"},{"key":"2025090709015497000_8.1.29.43","doi-asserted-by":"publisher","DOI":"10.1007\/s10354-008-0592-1"},{"key":"2025090709015497000_8.1.29.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.01.026"},{"key":"2025090709015497000_8.1.29.45","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.25503"},{"key":"2025090709015497000_8.1.29.46","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1517\/14656566.2015.998650","article-title":"Advances in pharmacotherapy for primary biliary cirrhosis","volume":"16","author":"Mousa","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"2025090709015497000_8.1.29.47","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"2025090709015497000_8.1.29.48","unstructured":"Intercept Pharmaceuticals, I., Ocaliva (obeticholic acid) [prescribing information]. New York, NY. May 2016."},{"key":"2025090709015497000_8.1.29.49","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26018"},{"key":"2025090709015497000_8.1.29.50","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04512.x"},{"key":"2025090709015497000_8.1.29.51","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/MCG.0b013e3181c115b3","article-title":"Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid","volume":"44","author":"Hazzan","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"2025090709015497000_8.1.29.52","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(86)70018-2"},{"key":"2025090709015497000_8.1.29.53","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/jhep.2003.50266","article-title":"Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis","volume":"38","author":"Hempfling","year":"2003","journal-title":"Hepatology"},{"key":"2025090709015497000_8.1.29.54","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510310209"},{"key":"2025090709015497000_8.1.29.55","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24525"},{"key":"2025090709015497000_8.1.29.56","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M209706200"},{"key":"2025090709015497000_8.1.29.57","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2008.04.171"},{"key":"2025090709015497000_8.1.29.58","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26019"},{"key":"2025090709015497000_8.1.29.59","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1016\/S0168-8278(14)60529-8","article-title":"P367 phase 2 study evaluating the efficacy and safety of Ustekinumab in patients with primary biliary cirrhosis who had an inadequate response to ursodeoxycholic acid","volume":"60","author":"Hirschfield","year":"2014","journal-title":"Journal of Hepatology"},{"key":"2025090709015497000_8.1.29.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2006.02.002"},{"key":"2025090709015497000_8.1.29.61","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jaut.2009.03.003","article-title":"X-linked primary immunodeficiencies as a bridge to better understanding X-chromosome related autoimmunity","volume":"33","author":"Pessach","year":"2009","journal-title":"J Autoimmun"},{"key":"2025090709015497000_8.1.29.62","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24630"},{"key":"2025090709015497000_8.1.29.63","doi-asserted-by":"publisher","DOI":"10.1096\/fj.01-0088com"},{"key":"2025090709015497000_8.1.29.64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra043898"},{"key":"2025090709015497000_8.1.29.65","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24044"},{"key":"2025090709015497000_8.1.29.66","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23238"},{"key":"2025090709015497000_8.1.29.67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.10.017"},{"key":"2025090709015497000_8.1.29.68","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.126"},{"key":"2025090709015497000_8.1.29.69","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.cgh.2013.09.021","article-title":"Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis","volume":"12","author":"Ozaslan","year":"2014","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Frontline Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/flgastro-2016-100741","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T16:02:16Z","timestamp":1757260936000},"score":1,"resource":{"primary":{"URL":"https:\/\/fg.bmj.com\/lookup\/doi\/10.1136\/flgastro-2016-100741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,3]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,7]]},"published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1136\/flgastro-2016-100741"],"URL":"https:\/\/doi.org\/10.1136\/flgastro-2016-100741","relation":{},"ISSN":["2041-4137","2041-4145"],"issn-type":[{"type":"print","value":"2041-4137"},{"type":"electronic","value":"2041-4145"}],"subject":[],"published":{"date-parts":[[2016,11,3]]}}}